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ABSTRACT: The kalimantacins are a family of hybrid polyketide-nonribosomal peptide derived natural products that display 
potent and selective antibiotic activity against multi-drug resistant strains of Staphylococcus aureus. Herein, we report the 
first total synthesis of kalimantacin A, in which three fragments are prepared and then united via Sonogashira and amide 
couplings. The enantioselective synthetic approach is convergent, unlocking routes to further kalimantacins and analogues 
for SAR studies and clinical evaluation.
The kalimantacins (1-3, Scheme 1A) are a family of bacte-
rial metabolites of mixed polyketide-nonribosomal peptide 
synthase (PKS-NRPS) origin that display potent antibiotic 
activity.1 Originally isolated from a soil sample collected 
from the West Kalimantan region of Borneo, they are pro-
duced by several bacteria including Pseudomonas fluo-
rescens and show high selectivity against multi-drug re-
sistant Staphylococcus species including methicillin-re-
sistant S. aureus (MRSA).2,3 The most active and abundant 
member is kalimantacin A 1 (also known as batumin),3 
whose relative and absolute stereochemistry was deter-
mined in 2015 through a combination of degradation stud-
ies and fragment synthesis.4 Preliminary clinical research 
has indicated that topical application of kalimantacin A is 
highly effective at disrupting and preventing the formation 
of S. aureus biofilms.5 
Another fascinating aspect of these natural products is their 
incorporation of β-branches, a structural feature present in 
many polyketides with important biological activities.6 
Uniquely, the kalimantacins contain three different and se-
quential types of β-branches at C-3, C-5 and C-7, as well as 
an additional methyl group at C-15. The biosynthetic mech-
anisms that control this remarkable selectivity have re-
cently been investigated.6 
The anti-staphylococcal activity of the kalimantacins de-
rives from inhibition of FabI, an enoyl-acyl carrier protein 
reductase enzyme that plays an essential role in fatty acid 
biosynthesis.7 X-ray crystallography and molecular dynam-
ics simulations have shown that the kalimantacin binding 
mode is unique, differing significantly from other FabI in-
hibitors.8 The stage is now set to gain further insights into  
Scheme 1. (A) Selected Kalimantacin Natural Products. 





the structure-activity relationships (SAR) of the kali-
mantacins, which will inspire future anti-staphylococcal 
drug development. To realize this potential, access to a li-
brary of analogues is now urgently required. Herein, we de-
scribe the first total synthesis of kalimantacin A 1 via an en-
antioselective, flexible and convergent approach. 
In our retrosynthetic analysis it was anticipated that kali-
mantacin A could be prepared from protected ester 4 
(Scheme 1B). From here, a late-stage amide coupling of 
(2R,3R)-3-hydroxybutanoic acid 5 and amine 6 was pro-
posed. The (E,Z)-diene was to be prepared via a So-
nogashira coupling of vinyl iodide 7 and alkyne 8, followed 
by stereoselective reduction of the enyne. It was envisaged 
that 7 could be assembled through lithiation of iodide 10 
and reaction with aldehyde 9. This convergent approach 
was designed to be versatile and readily adaptable in terms 
of both chain length and functionality to synthesize ana-
logues for SAR studies, as informed by X‐ray crystallog‐
raphy and molecular dynamics simulations with FabI. Fur-
thermore, the route was to be exploited for the preparation 
of putative biosynthetic intermediates to further probe the 
mechanisms of -branch incorporation in polyketide bio-
synthesis. 
Scheme 2. Semi-Synthetic Studies of Kalimantacin A. 
 
 
To begin, it was important to establish if the proposed pro-
tecting groups of 4 could be readily removed in the final 
stages of the total synthesis. Thus, kalimantacin A 1 was iso-
lated from cultures of P. fluorescens in titers of 65 mg/L us-
ing a procedure adapted from Mattheus et al.3 The acid was 
methylated with TMSCHN2 to ester 11 and the 19-hydroxyl 
was protected as the TBS ether to give 4 in 81% yield over 
two steps (Scheme 2A). To ensure these protecting groups 
could be removed cleanly, silyl ether 4 was treated with 
TBAF giving alcohol 11 in 89% yield. However, treatment of 
11 with LiOH at room temperature returned only starting 
material and on heating to 60 °C gave methyl ketone 12 via 
retro-aldol fragmentation of the -hydroxy ketone moiety 
(Scheme 2B). This compound is of interest for SAR studies 
as it closely resembles another natural product, 13, which 
was isolated from a fresh-water sponge and also displays 
activity against Gram-positive bacteria including S. aureus.9 
Hydrolysis of methyl ester 11 was achieved cleanly using 
porcine liver esterase (PLE), giving kalimantacin A 1 in 88% 
yield. 
Turning to the total synthesis of kalimantacin A, vinyl iodide 
7 (C-12 to C-20) was assembled from two building blocks, 
aldehyde 9 and alkyl iodide 10, which were both prepared 
on a multigram scale using previously reported procedures 
(see Supporting Information). Aldehyde 9 was synthesized 
in five steps and 68% overall yield starting from the chiral 
epoxide (S)-(−)-glycidol.10 Iodide 10 was prepared in three 
steps and 45% yield from a commercially available propio-
nylated Evans auxiliary.11 
 
Scheme 3. (A) Lithiation and Rearrangement of Iodide 
10. (B) Synthesis of Vinyl Iodide 7 (C-12 to C-20). 
 
 
Lithiation of iodide 10 using tBuLi was required for the cou-
pling with aldehyde 9. It was found that only poor conver-
sion to 15 was observed at low temperatures, with warm-
ing to 0 °C required to obtain full consumption of aldehyde 
9. However, at temperatures above ~−20 °C the alkyl lith‐
ium cyclized to give cyclobutylidene 14 (which was trapped 
by an electrophile), meaning careful temperature control 
was required (Scheme 3A).12-14 Additionally, if too large an 
excess of tBuLi was employed (>1.5 equivalents with re-
spect to iodide 10) then a secondary alcohol was formed via  
addition to aldehyde 9. Following optimization, desired al-
cohol 15 was isolated as a mixture   
 
 
Scheme 4. Synthesis of Alkyne 8 (C-1 to C-11). 
 
 
of diastereomers in 83% yield and the coupling was suc-
cessful on a multigram scale (Scheme 3B). Removal of the 
TMS group, using K2CO3 in MeOH followed by acetylation 
gave ester 16. The (E)-vinyl iodide was installed through 
hydrostannation of the alkyne to give 17, followed by in situ 
treatment with iodine to give 18. Deprotection was under-
taken at this stage to give the corresponding alcohol, as DDQ 
was found to give a complex mixture post-Sonogashira cou-
pling. Finally, the alcohol was transformed to mesylate 7 in 
75% yield over two steps. 
Preparation of alkyne 8 (C-1 to C-11) was based upon our 
previous work used in the structural assignment of kali-
mantacin A in which iodide 19 was used as a synthetic in-
termediate (Scheme 4).4 19 was subjected to lithium-halo-
gen exchange with tBuLi, then added to a freshly prepared 
solution of trimethylsilylmethylcopper to generate a mixed 
cuprate species in which the trimethylsilylmethyl group 
acts as an activating but non-transferable ligand.15,16 Conju-
gate addition to methyl but-2-ynoate proceeded with com-
plete stereocontrol for the (E)-alkene then the TBS group 
was cleaved under acidic conditions to liberate  alcohol 20 
in 83% yield over two steps. Oxidation was undertaken us-
ing Dess-Martin periodinane (DMP) to provide the alde-
hyde, which was treated with Grignard reagent 21, formed 
from the corresponding bromide.17 The resulting mixture of 
alcohols was again oxidized using DMP to give ketone 22 as 
a single enantiomer in 68% yield over three steps. The next 
stage was the introduction of the exo-methylene moiety 
which had been undertaken previously using Tour methyle-
nation conditions (Cp2ZrCl2, CH2I2, Zn).4,18 While this was 
successful, the reaction was capricious giving variable 
yields. Instead, it was found that a Lombardo methylenation 
(TiCl4, CH2Br2, Zn)19 was more robust and reproducible, 
providing 23 in 58% yield on a gram scale. Finally, depro-
tection was undertaken using K2CO3 in MeOH to give alkyne 
8. 
The Sonogashira coupling of vinyl iodide 7 and alkyne 8 
proceeded smoothly to give enyne 24 in 88% yield, thus 
 
 
Scheme 5. (A) Completing the Total Synthesis of Kalimantacin A. (B) Formation of Urea 30. 
 
 
completing the construction of the C-1 to C-20 carbon back-
bone of kalimantacin A 1 (Scheme 5A).  The next step of the 
synthesis required conversion of mesylate 24 to azide 25.  
Maeda and co-workers had reported that the steric bulk of 
a TBS group hindered nucleophilic substitutions in similarly 
protected 1,2-diols.20 However, heating mesylate 24 with 
NaN3 gave azide 25 in 85% yield. Reduction of azide 25 to 
amine 6 was achieved using a Staudinger reaction employ-
ing PPh3 in a mixture of THF and H2O.  This reaction re-
quired very careful degassing, as in the presence of air, ra-
ther than the required hydrolysis of the intermediate imino-
phosphorane 28, an aza-Wittig reaction with carbon diox-
ide occurred to give isocyanate 29, which further reacted to 
give dimeric urea species 30 (Scheme 5B).21,22 
The final fragment, acid 5, was prepared in two steps and 
76% yield from ethyl (R)-3-hydroxybutanoate (see Sup-
porting Information). Coupling of hydroxy acid 5 and amine 
6 was undertaken with no protection of the alcohol, thus 
obviating the need for further protecting group manipula-
tions. Using COMU and iPr2NEt, hydroxy-amide 26 was iso-
lated in 88% yield. Carbamoylation of 26 using trichloroa-
cetyl isocyanate, was followed by concomitant hydrolysis of 
both acetates with K2CO3 in MeOH. Oxidation of the result-
ant alcohol with DMP provided ketone 27 in 93% yield over 
three steps. 
The final key step of the total synthesis was the selective re-
duction of the (E)-enyne 27 to generate the required (E,Z)-
diene 4. In this case, commonly used hydrogenation with a 
poisoned palladium catalyst was avoided due to concerns of 
achieving the required chemoselectivity. Instead, 27 was 
treated with zinc activated with copper and silver, which 
gave the desired (E,Z)-diene 4 in 88% yield as a single iso-
mer by 1H NMR spectroscopy (J = 15 Hz and 11 Hz respec-
tively).23 The optical rotation of diene 4 prepared by total 
synthesis was in excellent agreement with the reference 
material obtained via protection of kalimantacin A 1 iso-
lated from cultures of P. fluorescens (Scheme 2). Finally, fol-
lowing the previously established deprotection and ester 
hydrolysis protocols (Scheme 2), completed the first total 
synthesis of kalimantacin A 1. The NMR spectral data and 
HPLC retention time were in accord with an authentic sam-
ple of the natural product (see Supporting Information). 
In conclusion, herein we have reported the first total syn-
thesis of the PKS-NRPS derived antibiotic natural product 
kalimantacin A 1. The enantioselective and convergent ap-
proach unites three fragments via Sonogashira and amide 
couplings. This flexible synthetic strategy, combined with 
recent insights into kalimantacin binding to FabI8 will ena-
ble SAR studies to be undertaken, thus paving the way for 
the design of future selective anti-staphylococcal drugs and 
their development for clinical assessment. Additionally, this 
route will be adapted for the synthesis of putative biosyn-
thetic intermediates to further probe the mechanisms of -
branch incorporation in kalimantacin biosynthesis. 
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